
|Articles|August 1, 2003
Targeted Therapy Will Have to Wait
Author(s)Paula Moyer
San Francisco - The future of melanoma treatment may include a union of surgical and medical oncology in which treatments such as interferon play an important role, according to Donald P. Lawrence, M.D. However, it is less likely that melanoma treatment will evolve to include genetically targeted therapies such as imatinib (Gleevec) in the future.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension
2
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
3
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
4
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
5











